RecruitingNot Applicable

Comparing Infectious Morbidity Among Women With Meconium-stained Amniotic Fluid at Term, Between Those Treated With Prophylactic Antibiotics Zinacef vs. Placebo

Israel182 participantsStarted 2025-02-18

Plain-language summary

Our randomized controlled double blind clinical trail aims to compare maternal and neonatal infectious morbidity between women with meconium-stained amniotic fluid treated with zinacef vs. placebo.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * singleton pregnancy at term * meconium-stained amniotic fluid Exclusion Criteria: * Intrauterine fetal death * GBS carriers * zinacef allergy * antibiotic treatment for other indication

What they're measuring

peripartum infections

Timeframe: 7 days

Trial details

NCT IDNCT06849037

SponsorWestern Galilee Hospital-Nahariya

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2028-02-13

Contact for this trial

Maya Frank Wolf, prof.

972-50-7887800 mayaw@gmc.gov.il

View on ClinicalTrials.gov More Meconium-stained Amniotic Fluid trials